CytomX Historical Financial Ratios

CTMX Stock

USD 1.02 0.06 6.25%

CytomX Therapeutics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0299, Days Sales Outstanding of 11.76 or Invested Capital of 0.0 will help investors to properly organize and evaluate CytomX Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

About CytomX Financial Ratios Analysis

CytomX TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate CytomX Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on CytomX financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across CytomX Therapeutics history.

CytomX Therapeutics Financial Ratios Chart

At this time, CytomX Therapeutics' Income Quality is fairly stable compared to the past year. ROE is likely to rise to 0.01 in 2024, whereas Price To Sales Ratio is likely to drop 1.07 in 2024.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Inventory Turnover Net Income Per Share Days Of Inventory On Hand

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing CytomX Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CytomX Therapeutics sales, a figure that is much harder to manipulate than other CytomX Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is CytomX Therapeutics dividend as a percentage of CytomX Therapeutics stock price. CytomX Therapeutics dividend yield is a measure of CytomX Therapeutics stock productivity, which can be interpreted as interest rate earned on an CytomX Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from CytomX Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Income Quality is fairly stable compared to the past year. ROE is likely to rise to 0.01 in 2024, whereas Price To Sales Ratio is likely to drop 1.07 in 2024.

	2023	2024 (projected)
Dividend Yield	0.0336	0.0299
Price To Sales Ratio	1.13	1.07

Dividend Yield Price To Sales Ratio

CytomX Therapeutics fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.25	-0.83	0.34	-0.35	0.38	0.14	0.09	-0.83	1.0	0.14	0.46	0.41	0.25	0.24	0.78	0.99	-0.53	-0.35	-0.83	-0.25	-0.05	-0.54	-0.25	-0.26	0.46
Dividend Yield	0.25		0.08	0.29	0.15	0.34	0.04	0.55	0.08	0.24	0.04	-0.05	-0.41	1.0	1.0	0.3	0.3	0.18	-0.15	-0.26	-0.77	-0.08	-0.1	-0.86	-0.95	-0.11
Ptb Ratio	-0.83	0.08		-0.48	0.41	-0.04	0.07	0.0	1.0	-0.82	0.06	-0.73	-0.49	0.08	0.08	-0.78	-0.84	0.62	0.21	0.76	-0.08	-0.02	0.44	-0.08	-0.09	-0.73
Days Sales Outstanding	0.34	0.29	-0.48		-0.35	-0.28	0.14	0.09	-0.48	0.34	0.15	0.85	0.13	0.29	0.3	0.37	0.37	-0.37	-0.14	-0.46	-0.28	-0.08	-0.25	-0.32	-0.3	0.78
Book Value Per Share	-0.35	0.15	0.41	-0.35		0.09	-0.37	0.16	0.41	-0.36	-0.38	-0.37	-0.87	0.16	0.15	0.04	-0.28	0.95	0.05	0.67	-0.16	-0.08	0.09	-0.16	-0.16	-0.33
Free Cash Flow Yield	0.38	0.34	-0.04	-0.28	0.09		0.56	0.49	-0.04	0.37	0.55	-0.3	0.06	0.34	0.31	0.44	0.42	0.09	-0.22	-0.4	-0.34	-0.09	-0.12	-0.33	-0.38	-0.19
Operating Cash Flow Per Share	0.14	0.04	0.07	0.14	-0.37	0.56		-0.02	0.07	0.14	1.0	0.09	0.47	0.04	0.04	0.02	0.11	-0.23	-0.04	-0.33	-0.04	0.01	0.03	-0.04	-0.08	0.18
Capex To Depreciation	0.09	0.55	0.0	0.09	0.16	0.49	-0.02		0.0	0.08	-0.03	-0.14	-0.4	0.55	0.54	0.38	0.21	0.23	-0.1	-0.31	-0.54	-0.11	-0.1	-0.56	-0.58	-0.12
Pb Ratio	-0.83	0.08	1.0	-0.48	0.41	-0.04	0.07	0.0		-0.82	0.06	-0.73	-0.49	0.08	0.08	-0.78	-0.84	0.62	0.21	0.76	-0.08	-0.02	0.44	-0.08	-0.09	-0.73
Ev To Sales	1.0	0.24	-0.82	0.34	-0.36	0.37	0.14	0.08	-0.82		0.14	0.46	0.41	0.24	0.23	0.78	0.98	-0.53	-0.35	-0.83	-0.24	-0.04	-0.54	-0.24	-0.25	0.46
Free Cash Flow Per Share	0.14	0.04	0.06	0.15	-0.38	0.55	1.0	-0.03	0.06	0.14		0.1	0.49	0.04	0.03	0.01	0.11	-0.25	-0.04	-0.34	-0.03	0.01	0.03	-0.03	-0.07	0.19
Roic	0.46	-0.05	-0.73	0.85	-0.37	-0.3	0.09	-0.14	-0.73	0.46	0.1		0.37	-0.05	-0.03	0.48	0.46	-0.45	0.01	-0.47	0.05	0.14	-0.15	0.03	0.06	0.98
Net Income Per Share	0.41	-0.41	-0.49	0.13	-0.87	0.06	0.47	-0.4	-0.49	0.41	0.49	0.37		-0.41	-0.4	0.02	0.32	-0.88	-0.02	-0.58	0.41	0.15	-0.04	0.43	0.43	0.4
Days Of Inventory On Hand	0.25	1.0	0.08	0.29	0.16	0.34	0.04	0.55	0.08	0.24	0.04	-0.05	-0.41		1.0	0.3	0.3	0.19	-0.15	-0.26	-0.78	-0.08	-0.1	-0.86	-0.95	-0.11
Payables Turnover	0.24	1.0	0.08	0.3	0.15	0.31	0.04	0.54	0.08	0.23	0.03	-0.03	-0.4	1.0		0.29	0.29	0.18	-0.15	-0.25	-0.75	-0.07	-0.09	-0.84	-0.94	-0.09
Average Inventory	0.78	0.3	-0.78	0.37	0.04	0.44	0.02	0.38	-0.78	0.78	0.01	0.48	0.02	0.3	0.29		0.86	-0.14	-0.17	-0.68	-0.3	0.04	-0.37	-0.3	-0.32	0.49
Capex To Revenue	0.99	0.3	-0.84	0.37	-0.28	0.42	0.11	0.21	-0.84	0.98	0.11	0.46	0.32	0.3	0.29	0.86		-0.46	-0.38	-0.84	-0.3	-0.09	-0.56	-0.3	-0.31	0.47
Cash Per Share	-0.53	0.18	0.62	-0.37	0.95	0.09	-0.23	0.23	0.62	-0.53	-0.25	-0.45	-0.88	0.19	0.18	-0.14	-0.46		0.22	0.73	-0.18	0.05	0.29	-0.19	-0.2	-0.42
Pocfratio	-0.35	-0.15	0.21	-0.14	0.05	-0.22	-0.04	-0.1	0.21	-0.35	-0.04	0.01	-0.02	-0.15	-0.15	-0.17	-0.38	0.22		0.22	0.15	0.94	0.88	0.15	0.16	-0.04
Interest Coverage	-0.83	-0.26	0.76	-0.46	0.67	-0.4	-0.33	-0.31	0.76	-0.83	-0.34	-0.47	-0.58	-0.26	-0.25	-0.68	-0.84	0.73	0.22		0.27	-0.02	0.36	0.27	0.28	-0.46
Payout Ratio	-0.25	-0.77	-0.08	-0.28	-0.16	-0.34	-0.04	-0.54	-0.08	-0.24	-0.03	0.05	0.41	-0.78	-0.75	-0.3	-0.3	-0.18	0.15	0.27		0.08	0.1	0.99	0.93	0.1
Capex To Operating Cash Flow	-0.05	-0.08	-0.02	-0.08	-0.08	-0.09	0.01	-0.11	-0.02	-0.04	0.01	0.14	0.15	-0.08	-0.07	0.04	-0.09	0.05	0.94	-0.02	0.08		0.8	0.08	0.08	0.08
Pfcf Ratio	-0.54	-0.1	0.44	-0.25	0.09	-0.12	0.03	-0.1	0.44	-0.54	0.03	-0.15	-0.04	-0.1	-0.09	-0.37	-0.56	0.29	0.88	0.36	0.1	0.8		0.1	0.1	-0.19
Days Payables Outstanding	-0.25	-0.86	-0.08	-0.32	-0.16	-0.33	-0.04	-0.56	-0.08	-0.24	-0.03	0.03	0.43	-0.86	-0.84	-0.3	-0.3	-0.19	0.15	0.27	0.99	0.08	0.1		0.97	0.09
Income Quality	-0.26	-0.95	-0.09	-0.3	-0.16	-0.38	-0.08	-0.58	-0.09	-0.25	-0.07	0.06	0.43	-0.95	-0.94	-0.32	-0.31	-0.2	0.16	0.28	0.93	0.08	0.1	0.97		0.11
Roe	0.46	-0.11	-0.73	0.78	-0.33	-0.19	0.18	-0.12	-0.73	0.46	0.19	0.98	0.4	-0.11	-0.09	0.49	0.47	-0.42	-0.04	-0.46	0.1	0.08	-0.19	0.09	0.11

Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	6.55	3.01	3.99	1.98	1.13	1.07
Ptb Ratio	7.37	6.07	3.11	(1.23)	(2.41)	(2.29)
Days Sales Outstanding	0.0825	2.9	4.14	247.07	12.38	11.76
Book Value Per Share	1.13	1.08	1.39	(1.3)	(0.64)	(0.61)
Free Cash Flow Yield	(0.38)	0.00976	(0.43)	(1.07)	(0.5)	(0.47)
Operating Cash Flow Per Share	(3.1)	0.11	(1.86)	(1.69)	(0.76)	(0.8)
Stock Based Compensation To Revenue	0.33	0.15	0.19	0.25	0.0846	0.0803
Capex To Depreciation	1.34	0.9	0.59	0.71	0.39	0.37
Pb Ratio	7.37	6.07	3.11	(1.23)	(2.41)	(2.29)
Ev To Sales	3.71	1.35	1.3	(1.32)	1.1	1.04
Free Cash Flow Per Share	(3.18)	0.0639	(1.88)	(1.71)	(0.77)	(0.81)
Roic	(1.45)	(0.48)	(0.75)	1.38	(0.0332)	(0.0348)
Net Income Per Share	(2.26)	(0.71)	(1.26)	(1.48)	(0.007709)	(0.008095)
Sales General And Administrative To Revenue	0.36	0.56	0.64	0.81	0.3	0.28
Research And Ddevelopement To Revenue	2.29	1.13	1.64	2.1	0.77	0.73
Capex To Revenue	0.0608	0.023	0.0231	0.0327	0.008299	0.007884
Cash Per Share	6.53	6.85	4.76	2.95	2.36	2.25
Pocfratio	(2.68)	57.47	(2.33)	(0.95)	(2.04)	(2.14)
Capex To Operating Cash Flow	(0.0502)	(0.0249)	0.44	(0.0135)	(0.0157)	(0.015)
Pfcf Ratio	(2.62)	102.46	(2.3)	(0.93)	(2.01)	(2.11)
Income Quality	1.37	(0.16)	1.42	1.12	98.48	103.4
Roe	(2.0)	(0.66)	(0.9)	1.13	0.012	0.0126
Ev To Operating Cash Flow	(1.52)	25.72	(0.76)	0.64	(1.98)	(2.08)
Pe Ratio	(3.68)	(9.19)	(3.44)	(1.08)	(201.06)	(191.01)
Ev To Free Cash Flow	(1.48)	45.85	(0.75)	0.63	(1.96)	(2.05)
Earnings Yield	(0.27)	(0.11)	(0.29)	(0.93)	(0.004974)	(0.005222)
Intangibles To Total Assets	0.006625	0.0059	0.005804	0.006991	0.008315	0.0079
Net Debt To E B I T D A	1.18	2.14	1.65	1.78	0.74	0.7
Current Ratio	3.54	3.21	2.92	1.55	1.17	1.11
Tangible Book Value Per Share	1.08	1.03	1.36	(1.33)	(0.67)	(0.63)
Receivables Turnover	4.4K	125.77	88.07	1.48	29.49	28.02
Graham Number	7.56	4.16	6.28	6.59	0.33	0.32
Shareholders Equity Per Share	1.13	1.08	1.39	(1.3)	(0.64)	(0.61)
Capex Per Share	0.0771	0.05	0.0251	0.0265	0.0114	0.0108
Graham Net Net	0.13	0.17	0.87	(1.92)	(0.98)	(0.93)
Revenue Per Share	1.27	2.17	1.08	0.81	1.37	0.84

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Cash Conversion Cycle

CytomX Historical Financial Ratios

About CytomX Financial Ratios Analysis

CytomX Therapeutics Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Inventory Turnover

CytomX Therapeutics fundamentals Correlations

CytomX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytomX Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for CytomX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Days Of Inventory On Hand	+ 1.0	Dividend Yield
Payables Turnover	+ 1.0	Dividend Yield
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Payables Turnover	+ 1.0	Days Of Inventory On Hand

Income Quality	- 0.95	Days Of Inventory On Hand
Income Quality	- 0.95	Dividend Yield
Income Quality	- 0.94	Payables Turnover
Cash Per Share	- 0.88	Net Income Per Share
Net Income Per Share	- 0.87	Book Value Per Share
Days Payables Outstanding	- 0.86	Days Of Inventory On Hand